Cytokinetics, Incorporated

Total Valuation

Cytokinetics, Incorporated carries a market capitalization of 10.78B, placing it among publicly traded companies globally. Its enterprise value stands at 8.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cytokinetics, Incorporated currently has 124.24M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 75.55, and the price-to-book ratio stands at -2.16.

Enterprise Valuation

Financial Position

Cytokinetics, Incorporated maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -155.91, indicating conservative leverage, while an interest coverage ratio of -5.51 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Cytokinetics, Incorporated's stock has gained approximately 159.77218% over the past 52 weeks. The 50-day moving average sits at 74.04, while the 200-day moving average is 65.15.

Income Statement

Over the trailing twelve months, Cytokinetics, Incorporated generated 105.82M in revenue and converted that into -829.61M in net income, yielding earnings per share of -6.84. EBITDA reached -629.04M, while operating income came in at -640.24M.

Balance Sheet

Cytokinetics, Incorporated holds 818.55M in cash and equivalents against 1.29B in total debt, resulting in a net debt position of 1.03B. Total book value stands at -3.69B, with working capital of 640.28M providing operational flexibility.

Cash Flow

Cytokinetics, Incorporated produced -523.85M in operating cash flow over the past twelve months. After subtracting -25.07M in capital expenditures, free cash flow totaled -548.92M - equivalent to -4.53 per share.

Margins

Cytokinetics, Incorporated operates with a gross margin of -201.22, reflecting its pricing power and cost economics. The operating margin of -605.06 and net profit margin of -784.02 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.

Scores

Cytokinetics, Incorporated posts an Altman Z-Score of -2.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.